Compositions and methods for treatment of prostate and other cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Compositions and Methods for Treatment of Prostate and Other Cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form. 124-. (canceled)25. An oligonucleotide consisting of the sequence of bases as set forth shown in SEQ ID NO 82 , wherein the oligonucleotide is modified to enhance in vivo stability.26. The oligonucleotide of claim 25 , wherein the oligonucleotide has a phosphorothioate backbone modification.27. The oligonucleotide of claim 25 , wherein the oligonucleotide has an MOE modification.28. A method for treatment of a cancer characterized by elevated expression of hsp27 as compared to non-cancerous tissue of the same type in an individual suffering from the cancer claim 25 , comprising the step of administering to the individual a therapeutic composition effective to reduce the amount of active hsp27 in the cancer cells claim 25 , wherein said therapeutic composition comprises an antisense oligonucleotide consisting of the sequence of bases as set forth shown in SEQ ID NO 82 claim 25 , wherein the oligonucleotide is modified to enhance in vivo stability.29. The method of claim 28 , wherein the cancer is selected from the group consisting of prostate claim 28 , bladder claim 28 , lung claim 28 , breast claim 28 , osteosarcoma claim 28 , pancreatic claim 28 , colon claim 28 , melanoma claim 28 , testicular claim 28 , ...

Compositions and methods for treatment of prostate and other cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

RNAi probes targeting cancer-related proteins

RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same

Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers. 118-. (canceled)19. A method for treating an endocrine-regulated cancer in a subject suffering from the endocrine-regulated cancer , comprising the step of administering to the subject a bispecific antisense oligonucleotide in an amount effective to reduce the effective levels of IGFBP-2 and/or IGFBP-5 in cells of the endocrine-regulated cancer , wherein substantially all of the bispecific antisense oligonucleotide is complementary to a portion of the gene encoding human IGFBP-2 and substantially all of the bispecific antisense oligonucleotide is also complementary to the gene encoding human IGFBP-5 , and wherein the bispecific antisense oligonucleotide is of sufficient length to act as an antisense inhibitor of human IGFBP-2 and human IGFBP-5 , wherein the endocrine-regulated cancer is breast , ovarian or colon cancer , and wherein the oligonucleotide consists of the series of bases as set forth in Seq. ID. No. 5.20. The method of wherein the bispecific oligonucleotide is administered in the form of a pharmaceutical composition made by combining the bispecific antisense oligonucleotide with a pharmaceutically acceptable carrier for intravenous claim 19 , intraperitoneal claim 19 , subcutaneous or oral administration.21. The method of claim 20 , wherein the oligonucleotide is modified to increase the stability of the antisense in vivo.22. The method of claim 21 , wherein the oligonucleotide is a phosphorothioate derivative.23. The method of claim 21 , wherein the oligonucleotide has 2′-O-methoxyethyl substitutions on the backbone.24. The method of claim 19 , wherein the oligonucleotide is modified to increase the stability of the antisense in vivo.25. The method of claim 24 , wherein ...

RNAi Probes Targeting Cancer-Related Proteins

RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment. 130-. (canceled)31. A double-stranded RNA molecule effective to inhibit expression of the secretory isoform of human clusterin (s-CLU) but not the nuclear isoform of human clusterin (n-CLU) said double stranded RNA molecules consisting of Seq ID Nos 58 and 59 , or Seq ID Nos. 61 and 62.32. The double-stranded RNA molecule of claim 31 , wherein the molecule consists of Seq ID Nos 58 and 59.33. The double-stranded RNA molecule of claim 31 , wherein the molecule consists of Seq ID Nos 61 and 62.34. A composition comprising first and second double-stranded RNA molecules effective to inhibit expression of the secretory isoform of human clusterin (s-CLU) but not the nuclear isoform of human clusterin (n-CLU) said double stranded RNA molecules consisting of Seq ID Nos 58 and 59 claim 31 , and Seq ID Nos. 61 and 62.35. A method of treating a cancer that expresses clusterin claim 31 , comprising administering to an individual in need of treatment a double-stranded RNA molecule effective to inhibit expression of the secretory isoform of human clusterin ...

Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same

Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers. 118-. (canceled)19. A method of inhibiting expression of both human IGFBP-2 and human IGFBP-5 comprising exposing cells expressing human IGFBP-2 and human IGFBP-5 to a bispecific antisense oligonucleotide consisting of Seq ID No. 5 , whereby expression of both human IGFBP-2 and human IGFBP-5 is inhibited.20. The method of wherein in the exposing step claim 19 , the cells are exposed to a pharmaceutical composition made by combining the bispecific antisense oligonucleotide with a pharmaceutically acceptable carrier for intravenous claim 19 , intraperitoneal claim 19 , subcutaneous or oral administration.21. The method of claim 20 , wherein the oligonucleotide is modified to increase the stability of the antisense in vivo.22. The method of claim 21 , wherein the oligonucleotide is a phosphorothioate derivative.23. The method of claim 21 , wherein the oligonucleotide has 2′-O-methoxyethyl substitutions on the backbone.24. The method of claim 19 , wherein the oligonucleotide is modified to increase the stability of the antisense in vivo.25. The method of claim 24 , wherein the oligonucleotide is a phosphorothioate derivative.26. The method of claim 24 , wherein the oligonucleotide has 2′-O-methoxyethyl substitutions on the backbone. This application claims the benefit of U.S. Provisional Application No. 60/350,046, filed Jan. 17, 2002, which is incorporated herein by reference.This present application relates to bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same in the treatment of endocrine-regulated tumors (for example, breast, prostate, ovarian and colon cancers).Prostate cancer is the most common cancer that affects men, and the second ...

Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same

Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.

Novel multilayered composite material utilizing quantum dot based photovoltaic effect for bi-directional brain-computer interface

A photovoltaic unit that includes a biological interface for sensing an electrical signal from the biological tissue, the biological interface including a multilayered piezoelectric amplifier including a composite impulse generating layer including a matrix of a piezo polymeric material and dispersed phases including piezo nanocrystals and carbon nanotubes. The photovoltaic unit also includes a transducer structure comprising a fiber substrate having quantum dots present on a receiving end of the fiber. The receiving end of the fiber receiving the electrical signal. The quantum dots converts the electrical signal to a light signal.

BI-DIRECTIONAL NEURON-ELECTRONIC DEVICE INTERFACE STRUCTURES

An interface structure for a biological environment including at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase. The piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer. The carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment. The carbon nanotubes further provide for the delivery of the byproducts of the free radical degradation from the biological environment to both piezo-nanocrystals and piezo-polymer. 1. An interface structure for a biological environment comprising:at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase, wherein the piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer, and the carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment, and delivery of byproducts of free radicals degradation from the biological environment to both piezo-nanocrystals and piezo-polymer material.2. The interface structure of claim 1 , wherein at least one biological environment interface layer is in contact with the surface of the composite impulse generating layer to provide a multi-layered interface structure claim 1 , the electrical impulses reaching the surface of ...

Compositions and Methods for Treatment of Prostate and Other Cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form. 124-. (canceled)25. A method for treatment of a cancer characterized by elevated expression of hsp27 as compared to non-cancerous tissue of the same type in an individual suffering from the cancer , comprising the step of administering to the individual a therapeutic composition effective to reduce the amount of active hsp27 in the cancer cells , wherein said therapeutic composition comprises an antisense oligonucleotide ,said antisense oligonucleotide having a length of 12 to 35 bases;said antisense oligonucleotide comprises at least 10 bases that are complementary to a subsequence of at least 10 contiguous bases within SEQ ID No: 91, andsaid subsequence of contiguous bases comprises at least 10 contiguous bases selected from the group consisting of(a) bases 551-580 of SEQ ID NO: 91;(b) bases 661-681 of SEQ ID NO: 91;(c) bases 744-764 of SEQ ID NO: 91;(d) bases 131-161 of SEQ ID NO: 91;(e) bases 241-261 of SEQ ID NO: 91; and(f) bases 361-371 of SEQ ID NO: 91.26. The method of claim 25 , wherein the cancer is bladder cancer.27. The method of claim 25 , wherein the cancer is pancreatic cancer.28. The method of claim 25 , wherein the cancer is lung cancer.29. The method of claim 25 , wherein the cancer is ...

Compositions and Methods for Treatment of Prostate and Other Cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form. 124-. (canceled)25. A pharmaceutical composition comprising a therapeutic agent effective to reduce the amount of active hsp27 in cancerous cells exposed to the therapeutic agent , and a pharmaceutically acceptable carrier , wherein the therapeutic agent comprises an RNAi molecule , wherein said RNAi molecule is from 18 to 23 nucleotides in length; wherein said RNAi molecule consists of a single-stranded sequence or two complementary sequences in a double stranded form that is/are the RNA counterpart of sequence of bases of the same length as the RNAi molecule within Seq ID No. 91 or complementary to Seq. ID No. 91.26. The composition of claim 25 , wherein the siRNA comprises the sequence of bases as set forth in any of Seq. ID No. 83-90.27. The composition of claim 25 , wherein the siRNA comprises the sequence of bases as set forth in Seq. ID No. 84.28. The composition of claim 25 , wherein said RNAi molecule consists of a single stranded sequence or two complementary sequences in a double stranded form that is/are the RNA counterpart of sequence of bases of the same length as the RNAi molecule within Seq ID No. 91 and/or is complementary to a series of bases selected from the group consisting of bases 131 ...

BI-DIRECTIONAL NEURON-ELECTRONIC DEVICE INTERFACE STRUCTURES

An interface structure for a biological environment including at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase. The piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer. The carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment. The carbon nanotubes further provide for the delivery of the byproducts of the free radical degradation from the biological environment to both piezo-nanocrystals and piezo-polymer. 1. An interface structure for a biological environment comprising:at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase, wherein the piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer, and the carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment, and delivery of byproducts of free radicals degradation from the biological environment to both piezo-nanocrystals and piezo-polymer material, wherein the at least one biological environmental interface layer is provided by a grid geometry comprised of a metal.2. The interface structure of claim 1 , wherein at least one biological environment interface layer is in contact with the surface of the composite impulse ...

Photosensitive multilayered composite material suitable for eye implants

A multilayered structure that includes a light receiving section including at least one layer including a noble metal composition and a metal oxide composition, the light transducing section transducing the energy of photons received to the energy of electrons. The structure further includes a piezo composite amplifier layer comprising a piezo polymer matrix, a first dispersed phase of piezo nanoparticles and a second dispersed phase of carbon nanotubes. The piezo composite amplifier amplifying a signal from the energy of the electrons received from the light receiving section using piezo-electric effects. The nanostructure further includes an environmental interface layer for delivering the amplified signal received from the piezo composite amplifier layer to a biological environment.

Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same

Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.

Compositions and methods for treatment of prostate and other cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

RNAi probes targeting cancer-related proteins

Compositions and methods for treatment of prostate and other cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

RNAi probes targeting cancer-related proteins

RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Rnai probes targeting cancer-related proteins

RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Rnai probes targeting cancer-related proteins

RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

RNAi probes targeting cancer-related proteins

RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.

Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Bispecific antisense oligonucleotides which consist essentially of a sequenc e of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.

Compositions and methods for treatment of prostate and other cancers

The present invention makes use of therapeutic agents which target heat shoc k protein (hsp) 27 in vivo to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp 27. In accordance with the invention, a therapeutic agent, f or example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp 27 mRNA, for example human hsp 27 mRNA, is administered to an idvidivual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically aceptable carrier, and package d in dosage unit form. A preferred dosage unit form is in injectable dosage un it form.

Rnai probes targeting cancer-related proteins

RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

RNA molecules that mediate degradation or blockage of translation of mRNA encoding clusterin, pharmaceutical composition containing it, and its use

RNAi-sekvenser som er nyttig som terapeutika i behandlingen av cancere av ulike typer, som inkluderer prostatacancer, sarkomer slik som osteosarkom, nyrecellekarcinom, brystcancer, blærecancer, lungecancer, koloncancer, ovariccancer, anaplastisk stor cellelymfom og melanon; og Alzheimer's sykdom. Disse sekvensene målsøker klustrin, IGFBP-5, IGFBP-2, både IGFBP-2 og -5 samtidig, Mitf, og B-raf Oppfinnelsen tilveiebringer ytterligere anvendelsen av disse RNAi-sekvensene i behandlingen av cancere av ulike typer, som inkluderer prostatacancer, sarkomer slik som osteosarkom, nyrecellekarcinom, brystcancer, blærecancer, lungecancer, koloncancer, ovariecancer, anaplastisk stor cellelymfom og melanom; og Alzheimer's sykdom, og en fremgangsmåte for å behandle slike tilstander gjennom administrasjonen av RNA-molekylene med RNAi-aktivitet til et individ, som inkluderer et menneskelig individ med behov for slik behandling. RNAi sequences useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanon; and Alzheimer's disease. These sequences target the clusters, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf The invention further provides the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method for treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, which includes a human subject in need of such treatment.

Oligonucleotides for treatment of prostate and other cancers

Compositions and uses thereof for the treatment of prostate and other cancers

Compositions and Methods for Treatment of Prostate and Other Cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Bio-directional neuron-electronic device interface structures

An interface structure for a biological environment including at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase. The piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer. The carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment. The carbon nanotubes further provide for the delivery of the byproducts of the free radical degradation from the biological environment to both piezo-nanocrystals and piezo-polymer.

RNAi Probes Targeting Cancer-Related Proteins

RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Compositions and methods for treatment of prostate and other cancers

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Photosensitive multilayered composite material suitable for eye implants

A multilayered structure that includes a light receiving section including at least one layer including a noble metal composition and a metal oxide composition, the light transducing section transducing the energy of photons received to the energy of electrons. The structure further includes a piezo composite amplifier layer comprising a piezo polymer matrix, a first dispersed phase of piezo nanoparticles and a second dispersed phase of carbon nanotubes. The piezo composite amplifier amplifying a signal from the energy of the electrons received from the light receiving section using piezo-electric effects. The nanostructure further includes an environmental interface layer for delivering the amplified signal received from the piezo composite amplifier layer to a biological environment.

Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen

A novel multilayered composite material utilizing quantum dot based photovoltaic effect for bi-directional brain-computer interface

A photovoltaic unit that includes a biological interface for sensing an electrical signal from the biological tissue, the biological interface including a multilayered piezoelectric amplifier including a composite impulse generating layer including a matrix of a piezo polymeric material and dispersed phases including piezo nanocrystals and carbon nanotubes. The photovoltaic unit also includes a transducer structure comprising a fiber substrate having quantum dots present on a receiving end of the fiber. The receiving end of the fiber receiving the electrical signal. The quantum dots converts the electrical signal to a light signal.